Anebulo Pharmaceuticals, Inc. (ANEB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0345691036
Anebulo Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.22 m USD |
| EBIT | -8.08 m USD |
| Net income | -8.48 m USD |
| Diluted EPS – continuing operations | -0.25 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
More stocks
- TAITRON COMPONENTS INC (TAIT)
- Lifeward Ltd. (LFWD)
- GLEN BURNIE BANCORP (GLBZ)
- Pharma-Bio Serv, Inc. (PBSV)
- Cellectar Biosciences, Inc. (CLRB)
- Clean Energy Technologies, Inc. (CETY)
- URBAN ONE, INC. (UONEK)
- VerifyMe, Inc. (VRME)
- UNIVERSAL SAFETY PRODUCTS, INC. (UUU)
- MedApp S.A (MDA.WA)
- CAMBER ENERGY, INC. (CEIN)
- Voip-pal.com Inc (VPLM)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.